Accessibility Menu

Filana Therapeutics(NASDAQ) SAVAW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-99%
5 YearN/A
1 YearN/A
1 Month-99%
$0.00
+0.00%
+0.00Today
Filana Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.032024-05-02
Filana Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-90.33%USD 0.302024-04-25
1 month-99.18%USD 3.562024-04-02
3 month-99.61%USD 7.352024-02-02
Since inception-99.05%USD 3.062024-01-04

Filana Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

$0.00

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

SAVAW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Filana Therapeutics

Cassava Sciences, Inc. is a biotechnology firm focused on developing therapies for neurodegenerative disorders. The company is advancing its lead therapeutic asset, simufilam, and a diagnostic tool, SavaDx, aimed at early detection of Alzheimer's disease.

Products and Services
  • Simufilam, a small molecule drug for neurodegenerative disorders
  • SavaDx, a blood-based diagnostic tool for Alzheimer's detection
  • Research and development in neurodegenerative therapies
Growth Outlook
  • Simufilam has completed Phase 2b clinical evaluation, showing promise
  • Increasing demand for Alzheimer's diagnostics supports SavaDx's potential
  • Market for neurodegenerative therapies is projected to grow significantly
Financial Highlights
  • Market capitalization stands at approximately $1.45 million
  • Stock price has fluctuated between $0.02 and $11.02 over the year
  • Recent trading volume reached over 2.5 million shares
Cassava Sciences, Inc. operates in the biotechnology sector, with a focus on innovative solutions for neurodegenerative diseases. The company's lead product, simufilam, has shown potential in clinical trials, positioning it as a key player in the Alzheimer's treatment landscape. Additionally, SavaDx aims to enhance early detection, addressing a critical need in the healthcare market. With a relatively low market capitalization and significant stock price fluctuations, the company presents a unique opportunity for investors interested in the biotechnology field. The growing demand for effective treatments and diagnostics in neurodegenerative disorders further underscores the potential for future growth.
AI Generated • Aug 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Austin, TX 78731, US

SAVAW Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Filana Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABEOAbeona Therapeutics Inc.
$5.92-1.99%
ANVSAnnovis Bio, Inc.
$1.72-4.97%
AVXLAnavex Life Sciences Corp.
$2.99-4.47%
AXSMAxsome Therapeutics, Inc.
$199.02-3.51%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$217.55-0.05%
PCGPG&E
$16.60-0.08%
BITOProShares Trust - ProShares Bitcoin ETF
$10.45-0.03%
IRENIren
$35.45-0.13%

Questions About SAVAW

What is the current price of Filana Therapeutics?

Filana Therapeutics is trading at N/A per share.

What is the 52-week range for Filana Therapeutics?

Over the past 52 weeks, Filana Therapeutics has traded between N/A and N/A.

How much debt does Filana Therapeutics have?

Filana Therapeutics total debt is unavailable.

How much cash does Filana Therapeutics have on hand?

Filana Therapeutics does not have cash on hand data available.

What is Filana Therapeutics’s dividend yield?

Filana Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services